Tyra Biosciences, Inc. (TYRA)

Market Cap	692.78M
Revenue (ttm)	n/a
Net Income (ttm)	-83.74M
Shares Out	52.60M
EPS (ttm)	-1.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	187,609
Open	13.00
Previous Close	12.78
Day's Range	12.88 - 13.46
52-Week Range	11.89 - 29.60
Beta	1.05
Analysts	Strong Buy
Price Target	30.50 (+131.59%)
Earnings Date	Mar 18, 2025

About TYRA

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and othe...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 15, 2021
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: TYRA
• Website: https://tyra.bio

Analyst Forecast

According to 6 analysts, the average rating for TYRA stock is "Strong Buy." The 12-month stock price forecast is $30.5, which is an increase of 131.59% from the latest price.

Price Target

$30.5

(131.59% upside)

Analyst Consensus: Strong Buy